Answers are grounded in this paper and cite their sources.
Atherosclerosis is a degenerative inflammatory disease of the intima of medium and large arterial vessels (Henderson, 1996; Ross, 1999). This disease, or group of diseases, is a leading cause of morbidity and mortality in western societies. Atherosclerosis may present itself in different manners, to a large extent depending on location and complications, such as myocardial infarction (MI), angina pectoris, cerebral ischaemia and peripheral artery disease. A multitude of factors are known to predispose to atherosclerosis, and these factors are generally referred to as risk factors or risk indicators (Hennekens, 1998). Generally accepted risk factors include cigarette smoking, physical inactivity, inherited or acquired dyslipidaemia, hypertension, diabetes, obesity, metabolic syndrome, menopause, hyperhomocysteinaemia, male gender and a positive family history of arterial disease (Glass & Witztum, 2001; Tegos et al, 2001). This extensive listing serves to illustrate that there is not one cause of atherosclerosis, but that atherosclerosis is a complex or multifactorial disease in which both inherited and acquired factors play a significant role. The notion that genes play an important role in arterial thrombosis may also be inferred from the finding that a familial component is often present in cases presenting with arterial disease (Hamsten, 1996; Friedlander et al, 2001). In most cases, the risk linked to a positive family history cannot be attributed to familial aggregation of 'classical' risk factors (Hamsten, 1996). Furthermore, the effect of a positive family history seems to be of particular relevance in patients at (apparently) low risk (Hamsten, 1996). In addition to the risk factors and indicators listed above, the blood coagulation system has also been alleged to determine the onset and outcome of atherosclerosis (Cooper et al, 2000). There are two principal reasons for this presumption. The first reason is that cleavage products from the coagulation system, e.g. thrombin, factor Xa, factor VIIa and activated protein C, may exert pro- and anti-inflammatory effects on endothelial cells and leucocytes (Esmon et al, 1991). The inflammatory responses of these cells to blood-borne factors are thought to be crucial to the atherosclerotic process (Buja & Willerson, 1994; Libby, 1996; Tracy, 1999). The second reason is that the formation of small blood clots that occlude major arteries, as occurs in, for instance, myocardial infarction or ischaemic stroke, represents the leading complication of atherosclerosis (Fuster et al, 1996; Rentrop, 2000). Subtle interindividual differences in the response of the coagulation system may modify the risk of arterial thrombosis. Thus, the search for haemostatic candidate genes and polymorphisms involved in the predisposition to atherosclerosis and arterial thrombosis represents an important step towards a more comprehensive understanding of the pathogenesis of the disease (Risch, 2000). Indeed, an impressive number of polymorphisms in genes coding for proteins of the haemostatic system have been claimed to influence risk (Lowe, 1997; Marian, 1998; Lane & Grant, 2000; Sykes et al, 2000; Winkelmann & Hager, 2000; Reiner et al, 2001a). Several issues complicate a review of the available data on candidate haemostatic genetic risk factors. The first problem is inherent to the two putative roles of the coagulation system, i.e. modulating the inflammatory response and determining the rate of clot formation, which are not always easily separated in an investigation of patients with atherosclerotic disease. Secondly, sources of data are heterogeneous, and both descriptive and analytical investigations have yielded a myriad of findings, which are often contradictory. Diversity of study design may contribute to the discrepancies, making direct comparisons between studies complicated. Many studies also suffer from a limited sample size, which is frequently too small to confirm or rule out the presence of a relevant epidemiological association between specific polymorphisms and cardiovascular disease. In addition, it is unlikely that specific haemostatic gene variations are, in isolation, very strong risk factors for arterial disease. More probable is the scenario in which haemostatic gene polymorphisms influence atherosclerosis or arterial thrombotic risk by interacting with other established genetic or acquired risk factors. Such interactions may not be apparent in all investigations because of the influence of factors such as sample size, ethnicity (which may also affect the nature and magnitude of gene–gene and gene–environmental interactions), selection and recall bias in case–control studies and clinical end-points. Another relevant point is that many candidate polymorphisms may be in linkage disequilibrium with actual disease-causing polymorphisms (a variation located somewhere in the regulatory or coding region of the same gene or even in another gene). The degree of disequilibrium may vary from population to population, a fact that may also be responsible for some of the discrepancies between studies analysing the same gene variation as a risk factor for arterial thrombosis. As will be discussed further in this review, it is our opinion that (because of the above-mentioned disputed results and unclear associations) phenotypic or genotypic analyses of the haemostatic system have no part to play in the current routine management of subjects with arterial thrombotic disease. In spite of the difficulties mentioned, the issue of the association between haemostatic risk factors and atherothrombotic disease remains highly relevant. Indeed, if the ultimate goal of characterizing phenotypic and genetic markers for arterial thrombotic risk was reached, it would enable one to establish individual profiles of arterial thrombotic risk and might eventually result in new and individualized prognostic and therapeutic measures. Gp Ia–IIa, also referred to as α2β1 integrin, is the major constitutive collagen receptor on the platelet surface that is involved in platelet adhesion to the subendothelial matrix (George, 2000). A silent dimorphism at nucleotide position 807 (C807T) of the GpIa–IIa gene was reported to affect α2β1 integrin density on platelets and collagen receptor activity (Kunicki et al, 1997; Kritzik et al, 1998). The C807T polymorphism is in tight linkage disequilibrium with a second Gp Ia–IIa polymorphism (G873A) and with other variations in the same gene (Kunicki et al, 1997; Kritzik et al, 1998). The 807T allele (linked to high α2β1 density) was associated with a significant 1·6-fold increased risk of MI in a large study investigating male patients undergoing coronary angiography (Santoso et al, 1999). The odds ratios for MI linked to the 807T allele increased with decreasing age, pointing to a more relevant role of this polymorphism in determining arterial thrombotic risk in young patients (Santoso et al, 1999). Subsequent reports also found the 807T allele to be a risk factor for MI and stroke, particularly in young patients (Carlsson et al, 1999; Moshfegh et al, 1999; Reiner et al, 2000), but others did not confirm these findings (Corral et al, 1999; Croft et al, 1999a; von Beckerath et al, 2000; Morita et al, 2001). To sum up, there are data indicating that the C807T Gp Ia–IIa polymorphism may be a risk factor for arterial thrombosis, but these data are not perfect, pointing to the need for additional studies dealing with much larger patient populations to resolve this issue (Beer et al, 2000). Gp Ib–V–IX is a constitutively active platelet receptor for von Willebrand factor (VWF) that mediates platelet binding to VWF present in the perivascular matrix (George, 2000). Two polymorphisms in the gene coding Gp Ibα were identified that affect the phenotype [HPA-2 and a variable number tandem repeat (VNTR); Lopez et al, 1992; Mazzucato et al, 1996; Li, C.Q. et al, 2000]. The HPA-2 alloantigen system is defined by the presence of a C to T substitution at nucleotide position 3550 (which results in a Thr-145Met substitution). The VNTR is a repeat of 39 bp in the macroglycopeptide region of the Gp Ibα, and the following alleles are known: D (four repeats), C (three repeats), B (two repeats) and A (one repeat). Each repeat results in the addition of 13 amino acids to the protein, and it is thought that the addition of amino acids modifies the distance between the VWF-binding domain and the platelet surface. The exact functional consequence of this alteration on platelet function is, however, poorly defined (Lopez et al, 1992; Mazzucato et al, 1996; Li, C.Q. et al, 2000). The HPA-2 and the VNTR polymorphisms are in tight linkage disequilibrium: HPA-2a (Thr at position 145) is linked to the C and D VNTRs, whereas HPA-2b (Met at position 145) is associated with the A and B VNTR alleles. The HPA-2 and the VNTR Gp Ibα polymorphisms were examined as risk factors for arterial thrombotic diseases in several investigations. Both positive associations (between HPA-2b and VNTR B allele and increased risk of MI and stroke) and negative findings were reported (Carlsson et al, 1997; Murata et al, 1997, 1998; Carter et al, 1998; Gonzalez-Conejero et al, 1998; Ardissino et al, 1999; Mercier et al, 2000; Sonoda et al, 2000). The contribution of Gp Ibα gene variations to arterial thrombosis is therefore unclear. Recently, a gene polymorphism has been described in the Kozak sequence of the Gp Ibα receptor (Afshar-Kharghan et al, 1999). This variation is a T/C dimorphism at nucleotide −5, which is located in the translation initiation codon of the Gp Ibα gene. The −5C allele is associated with more efficient mRNA translation and increased levels of the Ibα receptor on the platelet surface (Afshar-Kharghan et al, 1999). In a recent study, Frank et al (2001) investigated the −5C allele as a risk factor for MI and stroke in a population-based study involving relatively young women. The polymorphism had a neutral effect on the risk of stroke and, paradoxically, a trend towards protection against MI by the −5C allele (odds ratio 0·53) was observed (Frank et al, 2001). Further studies are certainly warranted to delineate better the role of this polymorphism in arterial thrombotic disease. Gp IIb–IIIa (also referred to as integrin αIIbβ3) mediates platelet aggregation by functioning as the fibrinogen receptor on the platelet surface. In platelets at rest, Gp IIb–IIIa exhibits low affinity for fibrinogen but, upon activation, this affinity is markedly increased. Gp IIb–IIIa may also serve as a receptor for VWF and other soluble ligands (Topol et al, 1999; George, 2000). A number of Gp IIb–IIIa gene variations have been described in the general population. The polymorphism that has received particular attention regarding its association with arterial disease is a common variation in the Gp IIIa gene: a T to C transition at nucleotide 1565, which results in a Pro to Leu substitution at amino acid position 33 (Newman et al, 1989). The Pro-33 allele (also referred to as PLA2) is known to exhibit a heterogeneous ethnic distribution and was claimed to result in increased platelet aggregability (Feng et al, 1999), but the exact functional consequences of this polymorphism are still unclear (Meiklejohn et al, 1999). PLA2 was associated with a 2·8-fold increased risk of MI in an initial report (Weiss et al, 1996). Since then, numerous studies have investigated the PLA2 allele as a risk factor for coronary thrombotic disease, and most of these studies did not confirm the hypothesis that this polymorphism modifies thrombotic risk (Marian et al, 1996; Herrmann et al, 1997; Ridker et al, 1997a; Samani & Lodwick, 1997; Durante-Mangoni et al, 1998; Mamotte et al, 1998; Aleksic et al, 2000). In some investigations, however, an association with early onset coronary atherosclerosis was observed (Carter et al, 1996a, 1997; Pastinen et al, 1998; Zotz et al, 1998; Ardissino et al, 1999; Mikkelsson et al, 1999). In most studies aimed at exploring the relationship between the PLA2 allele and stroke, a negative result was found (Carlsson et al, 1997; Ridker et al, 1997a), but at least one investigation suggested that this polymorphism increases the risk of cerebral vascular disease in relatively young subjects (Carter et al, 1998). In a recent study by Renner et al (2001), the PLA2 allele was found with similar frequency in 815 patients with documented peripheral artery disease and in two groups of control subjects. These conflicting results show that the relationship between the PLA2 polymorphism and arterial disease is difficult to judge, and will only be clarified when more data from larger samples become available. Another Gp IIb–IIIa gene variation that has been investigated in its association with arterial thrombotic disease is the Gp IIb Ile-843Ser polymorphism, with most studies yielding negative results (Hato et al, 1997; Böttiger et al, 1999, 2000). A recent study (Reiner et al 2001b) suggested that the Ser-843 allele is associated with increased risk of MI in young women (aged < 45 years) in the presence of other major risk factors for atherosclerosis such as smoking, positive family history of MI and high cholesterol levels. Further studies are warranted to confirm these findings. Fibrinogen is the precursor of fibrin, and its levels influence platelet aggregation, blood viscosity and endothelial cell injury, mechanisms that all play a role in atherosclerosis and arterial thrombosis. Thus, it is conceivable that, as a determinant of hypercoagulability, plasma fibrinogen level may influence the risk. Based on this hypothesis, several studies have addressed the risk of cardiovascular disease for high in comparison with low fibrinogen levels in plasma (Wilhelmsen et al, 1984; Yarnell et al, 1985; Kannel et al, 1987; Bolibar et al, 1993; Sweetnam et al, 1996). A of of these studies and that plasma fibrinogen levels the are associated with an increased risk of cardiovascular disease in both subjects and subjects et al, 1999). The effect of fibrinogen as a determinant of arterial thrombotic risk seems to be of other risk factors for arterial disease. Fibrinogen exhibits effects with other risk and high fibrinogen levels to the of of arterial thrombotic by pointing to a relevant prognostic role of fibrinogen levels in patients with arterial thrombotic disease. be mentioned, however, that fibrinogen is an and, the observed effect of fibrinogen levels may at least in the degree of the inflammatory that atherosclerotic disease. The fibrinogen is a two of and by genes located on the of polymorphisms have been identified in all in the coding the of attention has been to two in the gene: the polymorphism (a to A substitution at position in the and the polymorphism in the region These two polymorphisms are in linkage disequilibrium with The polymorphism is of particular because of its location an and a factor et al, Indeed, the substitution was found to be a determinant of plasma fibrinogen levels in different investigations et al, et al, 1996; et al, 1997; et al, 1997; et al, 1998). These findings several groups to for an association between this fibrinogen gene variation and the risk of arterial thrombosis, but conflicting results were reported (Carter et al, et al, 1997; et al, 1997; et al, 1997; et al, 1998; et al, 2001). In the results from studies this issue have not been and it be that there is that the relationship for arterial disease & Grant, 2000). Another fibrinogen gene variation that has some attention is the polymorphism in the coding region & 1996). was claimed that the allele increases clot et al, and this polymorphism has been investigated as a risk factor for arterial disease in a In the study, did not influence the risk of MI et al, 1998). In another the allele was associated with stroke and with increased risk of (Carter et al, 1999). The exact role of in thrombotic remains to be In a to A transition at nucleotide position in the of the coagulation factor gene was reported et al, 1996). is associated with et al, 1996; et al, 1999; et al, and increased risk of thrombosis et al, 1996; et al, 1997; et al, 1997; et al, 1997; et al, 1997; et al, 1998; et al, 1999). This polymorphism is in the general population, of in et al, 1996; et al, 1998; et al, 1998). results were reported regarding the role of as a risk factor for arterial thrombotic disease, and the issue remains et al, 1997; et al, 1997; et al, 1997; et al, 1997a; et al, 1997; et al, 1998; et al, et al, 1998; Ardissino et al, 1999; Croft et al, et al, 1999a; et al, 1999; et al, 1999; et al, 1999; et al, 1999; et al, 1999; Ridker et al, 1999; et al, 2000; Renner et al, et al, 2001). has been claimed that, in particular of patients instance, young subjects and may arterial thrombotic risk by interacting with established risk factors for et al, 1997a; et al, Recently, et al (2001) reported an effect between and the of in determining the risk of MI in women. The major of the blood coagulation is factor A recent study investigated individual differences in gene would predispose to thrombosis et al, 2000). of the region of the gene yielded polymorphisms that were two with D and the D allele was associated with levels of factor the and of D was claimed to against thrombosis. the did not influence the risk of coronary thrombotic disease in a case–control study involving et al, 2000). The to in the factor referred to as factor is the most genetic associated with thrombosis et al, 1994; et al, 1994; et al, 1994; & This factor is to activated protein and a and increased for thrombosis et al, 1993; et al, In to this towards the association of with arterial thrombotic disease is studies to that activated protein C or is a risk factor for arterial disease et al, et al, et al, et al, et al, et al, et al, Ridker et al, et al, Ardissino et al, 1999; et al, 1996; et al, 1997; et al, 1997; et al, 1997; et al, 1997; et al, 1999; et al, 1999; et al, 2000; Renner et al, As is the for the polymorphism, some investigations claimed that may contribute to by when other major risk factors are also present et al, et al, 1997; et al, instance, an increased risk of MI was present in young women also reported cigarette et al, the data that is not a major risk factor for arterial disease, but the may the risk by risk factors. factor is a plasma protein that as an and is activated by by factor and was one of the first coagulation genes for which between common polymorphisms and plasma levels have been The in this coagulation protein was by findings in the that levels were associated with arterial disease et al, These findings have been in another large study, the results the association between levels and arterial disease were not as it was not found to be an risk factor for MI for et al, Furthermore, additional studies did not confirm plasma levels to be a risk factor for arterial thrombotic disease et al, 1996; et al, 1997; et al, 1997; et al, 1997; et al, Several polymorphisms in the gene have been described and to influence plasma levels. attention has been on the in which is located in the domain of The allele is linked to and activity in plasma and has been investigated as a risk factor for arterial thrombosis in several studies & 1999). In a case–control study involving relatively young patients with familial the allele was reported to a strong effect against the of MI et al, larger case–control however, to confirm these findings, as the distribution of this polymorphism was the same in patients with arterial disease and control subjects et al, Lane et al, 1996; et al, 1997; et al, Ardissino et al, 1999). the association between plasma levels and and the findings the association of polymorphisms with arterial disease, the role of in determining arterial thrombotic risk is more at factor the influence of inherited and acquired factors. genes coding blood groups and VWF influence levels. familial aggregation of linked to blood group or has also been pointing to the of genetic determining 1999). plasma levels an established risk factor for thrombotic disease 2000). plasma activity levels have also been associated with increased risk of arterial thrombosis et al, 1999). The nature of this risk however, may be as is known to be an no specific in the gene has been identified that the levels or the increased risk of or arterial thrombosis. As with plasma VWF levels have been linked to increased risk of arterial thrombotic in several studies the issue et al, 1994; et al, 1997a; et al, 1997, 1999; et al, 1997; et al, 1998; et al, 1999; et al, 1999). no gene polymorphisms in the VWF have been to influence atherothrombotic risk. is a that is responsible for fibrin, the clot & et al, A transition in of the A gene that results in a to Leu substitution at amino acid position has been reported et al, This amino acid substitution is located to a and the allele the activity of for the is associated with increased and exhibit activity when with & 1998; et al, 1999). was claimed to against the of MI and stroke et al, et al, 1999; et al, 2000; et al, Such a effect however, not in other investigations et al, 2000; et al, 2000). As activity is to the putative effect of is and still investigation et al, et al, 2000; & 2000). exhibits a heterogeneous ethnic distribution et al, 2000), and a effect against thrombosis was also claimed et al, 1999; et al, et al, 1999; et al, 2000; et al, Renner et al, not observed et al, 2000; et al, 2000; et al, 2000). studies are therefore to better the role of this gene variation in thrombotic of the coagulation system, with activity are eventually in the formation of a The activity of these is by a group of proteins referred to as or coagulation of which the are protein C and protein in these coagulation are very in the general population, but result in a and increased risk of thrombosis. the role of and inherited in arterial disease is and it is unlikely that such contribute to arterial thrombotic risk. A is that of presenting with stroke of in may contribute to the thrombotic et al, 1998; et al, but, even in this clinical some still (Reiner et al, 2001a). is an protein of endothelial cells and to it its activity but of protein this crucial function in the protein C a of might play a role as a risk factor for thrombotic disease. a of are known in the gene of patients with thrombosis et al, 1997a; et al, 1997; et al, 1999, 2001). remains however, to the relationship between these and disease. reason for this is that functional are not in to that these are to gene Indeed, in data with the first reported in the did not in levels or functional activity et al, 1999). A particular amino acid occurs with of in et al, 1991). There is a that the A allele is more in of but this was not in a second study et al, 1997; et al, et al (2001) reported that the allele is linked to a increased risk of coronary disease in but not influence risk Another polymorphism that has been investigated regarding its with arterial disease is the to A substitution at nucleotide position in the gene that an substitution in the The allele was found to be more male patients with MI in control subjects in the of yielding an odds ratio for MI of et al, A particularly high risk was observed in relatively young patients (aged years) and in the presence of additional risk factors such as and metabolic risk factors increased In in two investigations, the polymorphism was not found to be a risk factor for coronary artery disease et al, or stroke et al, 2000). Recently, Li, et al reported that a polymorphism in the gene levels and is linked to a increased risk of coronary disease in the population. The same group also reported a significant association between of the allele and a increased risk of the of atherosclerosis in subjects et al, 2001). The role of in MI also received further from the of a in a family with arterial disease et al, 2000). the data are not but further to the notion that may be more important in arterial thrombotic disease in disease. is a that a major role in the of the coagulation the formation of a complex between factor factor and of its is a candidate risk factor for thrombotic however, with no or have been Recently, of the gene has yielded different polymorphisms and et al, 1998; et al, 1999). is not known these sequence variations affect plasma levels of with the of the for which levels have been claimed et al, 1999). is also polymorphisms influence thrombotic risk et al, 2000). There has been one that the is a risk factor for thrombosis et al, 1999), but this not be in a second study et al, 2000). A recent study reported on a new polymorphism in the of the gene This variation did not levels in a control population and not to influence the risk of coronary et al, 2000). The on endothelial cells is an important of the protein C 2000). Recently, the gene has been which the of for in this gene & 1999). Indeed, a in has been identified that may predispose patients to atherothrombotic disease et al, 1999). A recent study did not confirm the to be a risk factor for myocardial infarction et al, 2001). Further studies are in to the actual of gene variations in thrombotic is a of the as an important of activation, 1999). mRNA in and vascular cells was found in et al, 1992; et al, plasma levels have also been to increased risk of arterial thrombosis in a number of investigations, not & 1994; et al, 1994; et al, et al, 1996; et al, et al, 1997; et al, 1998; et al, 1998; & 1999; 2000). Several gene variations are known for the a variation at a repeat in a VNTR polymorphism in the and a polymorphism & 1999; & 1999). The dimorphism has been more investigated as to its and clinical The allele was reported to exhibit increased mRNA in comparison with the in in cell with the two alleles and with et al, In addition, the polymorphism is also known to determine with the associated with plasma et al, 1998; et al, 1998; et al, et al, 1998). The polymorphism has also been investigated as a risk factor for arterial thrombotic disease in numerous and results have from these Several investigations that the is a risk factor for coronary thrombosis in of patients with cardiovascular disease et al, et al, et al, 1998; et al, et al, 1999), but other studies did not confirm these findings et al, et al, Ridker et al, et al, 1999; et al, 2000). A recent found that the allele is associated with a in the risk of MI et al, also referred to as is a plasma that mediates and clot by 1999). plasma levels have been associated with increased risk of coronary thrombotic disease et al, 1993; et al, polymorphisms have been reported for the gene et al, 1996). has been reported that an polymorphism in the gene the of et al, 1999). The for the polymorphism has been associated with a increased risk of MI in the study et al, but this finding not in other investigations et al, 1996; Ridker et al, et al, 1998). Thus, the role of this variation in arterial disease is Recently, gene polymorphisms have been described et al, 2000). of the polymorphisms identified are in strong linkage disequilibrium with the polymorphism and influence The other variations were silent and apparent effect on et al, 2000). The of these polymorphisms with arterial disease is as This review of studies that at the relationship between proteins from the blood coagulation and and arterial thrombosis and The that is from these studies is that levels of some haemostatic factors may arterial disease. A is plasma fibrinogen the of this relationship between factor and arterial disease, one that levels of proteins cause arterial disease and are risk and not indicators of the atherosclerotic for this hypothesis has been in studies that at the relationship between genetic markers in coagulation protein genes and disease. The results from such studies are and conflicting at and positive results were more often not found in analyses from this that factor levels or play a role in arterial disease, but only in of patients young and that differences in study design for the the findings as indicating that a relevant relationship between genetic of the coagulation and and atherothrombotic disease is are in the and no need for factor in the routine management of patients with cardiovascular disease. In to and in the only the and studies will was by and The of is also
No takes yet. Share an insight, caveat, or question.
Franco et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: